- Home
- INKT vs GLTO Comparison
INKT vs GLTO Comparison
Compare INKT & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | GLTO |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 1.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INKT | GLTO |
|---|---|---|
| Price | $10.93 | $29.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $35.00 | ★ $43.67 |
| AVG Volume (30 Days) | 5.3K | ★ 318.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $2.01 |
| 52 Week High | $76.00 | $38.33 |
Technical Indicators
Market Signals| Indicator | INKT | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 54.82 |
| Support Level | $6.85 | $3.32 |
| Resistance Level | $11.65 | $32.86 |
| Average True Range (ATR) | 0.31 | 3.02 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 4.25 | 65.04 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.